AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with melanoma and...
Hence then, the article about multitude therapeutics announces encouraging interim phase i ii results from ongoing first in human study evaluating its muc18 directed antibody drug conjugate amt 253 in melanoma and other advanced solid tumors at the 2025 esmo annual me was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Me )
Also on site :
- Trump’s Christmas Eve calls with children asking about Santa’s whereabouts are steeped in partisan politics
- Update: Flood watch affecting 5 Freeway north of LA until early Friday evening caused by persistent downpours
- Ukraine-Russia war latest: Zelensky awaits Putin response to new peace plan while Christmas Eve blast kills 3 in Moscow